Showing results (51-60 of 74) with videos related to
Sort By:
Pageof 8
Advances in Therapy|September 11, 2025
Healthcare Costs Associated with Adverse Events in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Claims-Based StudyJeff Schein, Maryaline Catillon, Anaïs Lemyre, et al.Journal of Child and Adolescent Psychopharmacology|October 7, 2024
Quality of Life and Outcomes Associated with Adverse Effects in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder and Their Parents/CaregiversJeff Schein, Martin Cloutier, Marjolaine Gauthier-Loiselle, et al.Clinical Drug Investigation|October 3, 2014
Steady-state bioavailability of extended-release methylphenidate (MPH-MLR) capsule vs. immediate-release methylphenidate tablets in healthy adult volunteersAkwete Adjei, Robert J Kupper, Nathan S Teuscher, et al.Current Medical Research and Opinion|August 24, 2021
Treatment patterns among adults with attention-deficit/hyperactivity disorder in the United States: a retrospective claims studyJeff Schein, Ann Childress, Julie Adams, et al.Journal of Child and Adolescent Psychopharmacology|February 19, 2025
Safety and Efficacy of Brexpiprazole in the Treatment of Irritability Associated with Autism Spectrum Disorder: An 8-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and 26-Week Open-Label Extension in Children and AdolescentsCaroline Ward, Ann Childress, Krista Martinko, et al.CNS Drugs|October 7, 2024
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity DisorderAnn Childress, Andrew J Cutler, Lenard A Adler, et al.Journal of Managed Care & Specialty Pharmacy|November 22, 2021
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspectiveJeff Schein, Lenard A Adler, Ann Childress, et al.Journal of the American Academy of Child and Adolescent Psychiatry|December 20, 2011
A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorderTimothy E Wilens, Oscar Bukstein, Matthew Brams, et al.Journal of Attention Disorders|February 15, 2013
ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 YearsFrank A López, Ann Childress, Ben Adeyi, et al.Journal of Medical Economics|January 24, 2022
Economic burden of attention-deficit/hyperactivity disorder among children and adolescents in the United States: a societal perspectiveJeff Schein, Lenard A Adler, Ann Childress, et al.Pageof 8